Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Investors who are eligible will let you know how we make out.I think with $7,000,000 a sec investigation and guilty charge we will do ok.
what a great day for flippers ,when shoukd we buy back in ? when we see volume ,this is too easy LOL
Great stock to flip speaks volumes .ENZC said it does not care about daily stock price so flip away.Everyone is making bank from flipping a perfect otc stock with no loyalty for longs . Big holders can buy move the sp up and a few days later sell and it tanks easy peasy . Change your stategy and make money flipping,this is just way to easy.
NO audit NO money thanks again Charles.lied months ago it would be finished in a few weeks with No apology or explanation ! The longest financial audit EVER!!! I hate people who lie, then praise some righteous bullshit .
NO audit NO money ,thanks Charles
NO audit NO money
Recieved letter of determination of clain today.
NO audit no money for U
Patent news out at today @1130 not helping stock price!!!!! enzc refuses to help or assist long investors.Now peeps will tell you how they made money flipping sell high wait and buy low after the fact . What a pos enzc has been for 2 years,still waiting for a simple financial audit!!!!
ENZC reinforces its just a OTC piece of shit .They have proven for 2 years they dont care about their long investors.ENZC continue to drag out a financial audit,the market responds with with all the cheerleading and fortune cookie statements . Charles missed a perfect opertunity to help the SP with a little bit of good news yesterday, to prevent the continued abuse of long investors .ENZC just plain SUCK! When are they going to help their LONG investors???
enzc are plain and simple compulsive liars.The SEC should be pressing fraud charges sooooooon .
realy hard to have any faith or trust when ENZC are compulsive liars!
Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies.
COLLEGE STATION, TX / ACCESSWIRE / September -16, 2022/ Enzolytics, Inc. (OTC Markets "ENZC" or the "Company").
Enzolytics, Inc. announces a collaboration with Abveris, a division of Twist Bioscience Corporation, to discover fully human monoclonal antibodies against multiple viruses. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services.
The collaboration makes possible the combination of the synergistic technologies of the two companies in discovering monoclonal antibodies against numerous pathogenic viruses. Under the terms of the collaboration, Abveris (also known as Twist Boston) will utilize human patient donor peripheral blood mononuclear cell (PBMC) samples and peptide screening tools provided by Enzolytics to perform rapid B cell screening and identify antigen-binding antibodies for further characterization by Enzolytics. The companies will initially focus on discovering antibodies targeting SARS-CoV-2.
Enzolytics’ focus is on producing fully human monoclonal antibodies targeting multiple viral infectious diseases, including SARS-CoV-2, HIV-1, Feline Leukemia virus, and Feline Immunodeficiency virus. The Company's antibodies are produced from human "immune-B cells" obtained from convalescent individuals who have recovered from the target virus. The Company’s Artificial Intelligence (AI) platform is used to identify highly conserved, immutable target sites on viruses. Production of antibodies targeting these conserved sites on the viruses will result in the production of antibodies that are not rendered ineffective by virus mutation. These fully human monoclonal antibodies have the original antibody affinity and specificity and minimized chances of immunogenicity.
This collaboration allows Enzolytics to significantly expedite the production of monoclonal antibodies against the numerous human and animal viruses which Enzolytics has analyzed using its AI platform.
"We have been impressed by Abveris' track record of discovering and delivering therapeutic antibodies," said Dr. Gaurav Chandra, Chief Operating Officer of Enzolytics. "To efficiently block COVID-19 infections and transmission, we need to get high levels of secretory IgA, reflecting mucosal immunity. Abveris will identify promising monoclonal antibody candidates via function-forward, high-resolution screening under expedited timelines.
This partnership with Abveris complements our efforts to significantly expand our antibody portfolio. We look forward to collaborating with Abveris to move us closer to our goal of expediently developing therapies for both human and veterinary use."
ITV-1 anti-HIV Therapeutic
August 22, 2022
The Company’s ITV-1 anti-HIV therapeutic is in production and the Company is proceeding with steps to advance it through approval under the European Medicines Act (EMA). Toxicology studies are ongoing and near completion in the Company’s partnering California lab. The results of these tests will be reported as they are completed. Simultaneously, the ITV-1 therapeutic is proceeding through the necessary multi-stage production process in the Company’s partnering lab in Europe. The current ongoing production of ITV-1 will be used in clinical trials conducted under the EMA guidelines. Early production of ITV-1 will be submitted to health care entities in Africa, where testing and use of the therapeutics are expected to be made possible before EMA approval.
To meet EMA requirements, the Company has engaged European medical specialists to guide the therapeutics through the EMA process. The Company's Board Advisor, Dr. Lachezar Ivanov, and the Company CSO Harry Zhabilov, in conjunction with medical field advisors in Europe, are managing this process for introducing ITV-1 to E.U. countries under the EMA.
The Company is also focused on providing its anti-HIV therapeutics to the African continent due to the tremendous need in African countries for effective and affordable treatment. The Company plans to make ITV-1 available in countries in Africa, including Rwanda, the Democratic Republic of Congo, Angola, Kenya, and South Africa and the Company is coordinating the introduction of ITV-1 for use in these countries as soon as possible. This is significant, recognizing that out of the 39 million HIV-positive people worldwide, 69% live in sub-Saharan Africa. There are roughly 23.8 million infected persons in all of Africa. In addition, 91% of the world's HIV-positive children live in Africa. More than 45% of the African population who have HIV do not have any access to the anti-retroviral treatment used in other countries to treat but not cure HIV.
The beneficial effects of ITV-1 are significant and will be complimentary to other treatments but at a lower cost and available to the over 45% of infected individuals in Africa who have no access to any treatment, including antiretrovirals which are used in other countries around the world for treating HIV patients.
Positive Therapeutic Effects of ITV-1
Prior European clinical trials have demonstrated the following beneficial effects of ITV-1.
ITV-1 inhibits the infection of CD4 T-cells by HIV.
It reduces HIV viral loads.
Replaces or complements current anti-retroviral therapies.
It is potentially less costly and much less toxic.
It may be effective as a periodic therapy instead of a daily one.
It is unaffected by HIV mutations that can hamper anti-retroviral therapies (HAART).
Tests have shown an 80.5% drop in viral loads.
It raises CD4 T-cell counts to healthier levels, with a 68% increase in CD4+T-lymphocytes.
Use achieved an increase in the CD4/CD8 index.
It demonstrated an excellent effect on opportunistic infections.
It had good compatibility with other anti-retroviral drugs.
There was good tolerance without any side effects.
Use resulted in a decrease in the absolute number and the relative percent of CD8 lymphocytes.
It boosts the immune system to fight HIV infections.
ITV-1 has benefits that anti-retrovirals do not and may be used in situations where anti-retrovirals are not appropriate.
Anti-retroviral therapies have serious side effects. In addition, they do not cure a patient.
HIV infections are most treatable during their earlier stages, and patients cannot take antiretrovirals during earlier stages since drug resistance often develops.
There are limited or few treatment options available when viral load and CD4 cell counts are at their worst, i.e., AIDS.
The Company’s IPF Immune ™ dietary supplement
Enzolytics IPF Immune™ will be available in numerous sales outlets throughout the U.S. Delays in producing sufficient quantiles for the market are being addressed. These delays have provided time for increasing production capability to meet demand. The company’s market research has indicated significant demand for IPF Immune™.
The nutritional supplement market is large and growing annually. The global dietary supplements market was valued at $151.9 Billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.9% from 2022 to 2030. Over the forecast period, increasing consumer awareness of personal health and wellbeing is expected to be a key driving factor for dietary supplements. In addition, increasing dependence on supplements to fulfill the nutrient requirements owing to their high convenience is expected to drive the market upwardly over the forecast period. The U.S. market for dietary supplements leads the North American market and matches the European market.
The Company is making plans for the sale of the IPF Immune™ product in numerous countries in Europe, Latin America, Australia, and Canada. These plans include engaging with promoters and distribution representatives in these countries. Just like in the U.S., each country's nutritional supplement market is large and growing rapidly. In addition, because the product is produced in Europe, providing the product to European markets will be easier and less expensive, providing a more significant profit margin to the Company.
Regarding marketing, the Company has engaged a marketing specialty firm that will use "computer analytics" to target individuals who are specifically searching for a nutrition supplement with the properties of IPF Immune™. Such focus will greatly increase sales of this new product while reducing advertising costs.
Production of Monoclonal Antibodies
Enzolytics' U.S. lab at the A&M Institute for Preclinical Studies is focused on producing fully human monoclonal antibodies targeting multiple infectious disease?s?, including SARS-CoV-2, HIV-1, Feline Leukemia virus and Feline Immunodeficiency virus. The lab uses the Company's proprietary methodology for producing fully human monoclonal antibodies which target conserved, immutable sites on the viruses, thereby avoiding ineffectiveness due to virus mutation.
The methodology implemented by the Company to produce monoclonal antibodies is proprietary and the subject of pending international patent applications. In the initial process step, Artificial Intelligence (computer analysis - A.I.) is used to identify conserved, immutable epitopes on the target virus utilizing Enzolytics' proprietary A.I. platform invented by Dr. Gaurav Chandra the Company COO. In the A.I. initial analysis step, the sequences (structure) of over 2 million Coronavirus isolates have been analyzed. From that analysis, 19 epitopes (target sites) have been identified as immutable and conserved across all 2 million isolates. The Company production process is then employed to produce monoclonal antibodies targeting these identified conserved sites.
As a part of this process, 3 Dimensional models of these conserved targets are generated, and the targets are analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. Then Enzolytics’ scientists produce multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus.
Enzolytics' methodology for producing monoclonal antibodies is innovative, unlike those employed by other biotech companies. The Company's antibodies are produced from human "immune-B cells," obtained from convalescent individuals who have recovered from the target virus. The Company's monoclonal antibodies are not "humanized" but are fully human monoclonal antibodies where the original antibody affinity and specificity are maintained, and the chances of immunogenicity are minimized.
The team then produces broadly neutralizing antibodies using various techniques. The Company is partnering with a biotech company with specialized capabilities for accelerating process steps to speed production. This new strategy will allow the Company to reduce the time to completion significantly. In addition to the already produced anti-HIV monoclonal antibody Clone 3, the Company is focused on producing monoclonal antibodies for treating HIV-1, SARS-CoV-2, SARS-CoV-2, Feline Leukemia Virus (FeLV), and Feline Immunodeficiency Virus (FIV). However, the Company has identified the conserved and immutable epitope sites on 20 human and animal viruses, against which it plans to produce monoclonal antibodies for the treatment of those viruses.
This production process is highly technical and time-consuming. The process begins by creating the target epitopes identified using A.I. as sites fully conserved across millions of epitopes of the targeted virus. Then, the antibody creation process is conducted such that the produced antibodies are designed to neutralize by binding to these “Achilles heel” sites on the targeted virus.
Once produced, the monoclonal antibodies are tested for binding and neutralizing activity. These characteristics are confirmed by the Company's partnering laboratories, Genscript Labs, and the University of Strasbourg, France. After confirming antibody activity, the Company's CDMO partner Samsung Biologics produces recombinant antibodies in their proprietary, FDA-approved stable CHO cell line suitable for Clinical Application. https://www.bloomberg.com/press-releases/2021-10-07/enzolytics-inc-and-samsung-biologics-announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2.
The plans are in place to proceed with animal studies to demonstrate the in-vivo efficacy of the monoclonal antibodies in partnership with European partners.
There is a significant role for mucosal immunity and secretory as well as circulating IgA antibodies in COVID-19. Therefore, Enzolytics focus on mucosal immunity for COVID-19. Enzolytics firmly believe that mucosal immunity can be exploited for beneficial diagnostic, therapeutic, or prophylactic purposes.
Enzolytics has created Class switched IgA1/2 Clone 3 Antibodies. This therapy will expectedly provide a protective immunological defense against an initial exposure to HIV virus at mucosal surfaces, such as occurs in the passage of the virus from mother to child through maternal breastfeeding. HIV mucosal infection plays a critical role in virus transmission and AIDS pathogenesis, affecting mucosal surfaces of the gastrointestinal tract early on by depleting CD4+ T helper cells independently of the virus transmission route. Although current anti-retroviral therapy helps control HIV infection in most patients, it cannot eradicate the virus from the human host. Therefore, the development and use of HIV microbicides (i.e., topical pre-exposure prophylaxis) have become the most promising approach to preventing HIV transmission. Thus, the development of Class switched Clone 3 IgA1/IgA2 is highly significant.
Enzolytics is collaborating with companies to produce monoclonal antibodies for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV). Enzolytics has already identified a partner for the monoclonal antibodies targeting Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus.
Enzolytics Patent Portfolio and Strategy
As of August 19, 2022, the Company has three (3) pending Patent Cooperation Treaty (PCT) Patent applications covering its fully human monoclonal antibodies targeting the CoronaVirus and HIV. Additional patent applications are being prepared to cover the numerous viruses against which the Company plans to produce monoclonal antibodies.
In the first PCT Patent Office Official Action on the Company’s International Patent Application covering its discovery and exclusive claim to conserved antigens and epitopes of the HIV virus, the PCT International Search Report concluded that inventions claimed therein are novel and inventive and thus will expectedly be issued in final international patents. The Company’s International Patent application covers (1) the discovered highly conserved antigens and epitopes (sites) on the HIV virus, (2) antibodies that bind to the disclosed antigens and epitopes, (3) vaccines based on the antigens, (4) methods of treating, preventing, or reducing the risks of HIV infection with the antigens or binding proteins, and (5) methods and kits for detecting or diagnosing infection by HIV using the antigens or binding proteins.
The Company discovered the claimed virus sites through computer analysis (Artificial Intelligence (A.I.)), wherein tens of thousands of HIV isolates were curated to identify these critical, conserved, immutable epitopes on the virus. These sites are now claimed as patentable based on their novel specificity and the finding that they are conserved on the HIV virus. This is significant in that by producing antibodies that attack these conserved, immutable sites, the virus can be neutralized rather than unaffected due to virus mutation that avoids the therapeutic.
The Company is producing fully human monoclonal antibodies against these claimed sites. The International Patent Office has now confirmed these discoveries to be novel and inventive, capable of being patented and claimed exclusively for a 20-year term in every member country under the Patent Cooperation Treat in which the Company pursues these claims.
Due to the novel nature of the Company’s discoveries, the Company fully expects the same favorable results in the PCT Patent Office for its pending applications covering epitopes (binding sites) on the CoronaVirus (covering all variants), on the Monkeypox Virus, and on numerous animal viruses, namely Feline Leukemia Virus (FeLV), Feline Immunodeficiency Virus (FIV), Elephant Endotheliotropic Virus, Equine Infectious Anemia, and Koala Retrovirus. The Company fully expects the issuance of multiple international patents covering these discoveries.
The Company's PCT applications also cover the identification of highly conserved antigens and epitopes of these viruses that can be used in the production of antibodies and the production of vaccines for treating, preventing, or reducing the risks of infections caused by these viruses.
The patents also cover the discovery of using these identified antigens and epitopes as targets for detecting and diagnosing viral infection. This is a significant development since these patents cover treatment and prevention and target detecting and diagnosing infections for all viruses pursued by Enzolytics.
In the Company's unique process, computer analysis (A.I.) was used to identify conserved, immutable epitopes on the target virus utilizing Enzolytics' proprietary A.I. platform invented by Dr. Gaurav Chandra, the Company COO. The sequences (structure) of over 87,500 HIV isolates were analyzed in the initial A.I. step for HIV, and for the Coronavirus, over 2 million SARS-CoV-2 virus isolates were curated. In the case of HIV, eight (8) epitopes (target sites) were identified and claimed in the Company's PCT application. As a part of this process, 3 Dimensional models of these conserved targets were generated, and the targets were analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. From this, Enzolytics' scientists are producing multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus. As a result, the monoclonal antibodies produced against these targets will be universal, durable, broadly neutralizing, and unaffected by virus mutation. In the case of SARS-CoV-2, nineteen (19) conserved sites were identified and are claimed in the Company's pending PCT applications.
The Company considers the forthcoming patent protection highly significant in view of the following facts:
For a monoclonal antibody to be effective (that is, to be fully capable of neutralizing a virus), it must target an immutable site on the virus. Otherwise, a virus mutation will render the therapeutic ineffective.
The Company has analyzed over 2 million Coronavirus isolates and over 87,000 HIV isolates and has identified 19 conserved sites (98 to 99% conserved) on the Coronavirus and 8 conserved sites on the HIV virus.
The Company's patent claims cover these findings. From the most recent PCT International Patent Office Action, claims have been recognized as novel and Inventive. They thus can be expected to issue in the U.S. and many foreign countries pursued. The Company claims the use of anyone identified epitope or any combination of any of the multiple identified epitopes in any of the following ways:
For producing a therapeutic monoclonal antibody to treat HIV or the CoronaVirus.
For producing a vaccine against HIV or the CoronaVirus.
For producing related prophylactic/therapeutic methods relating to the epitopes/antigens.
For use in any diagnostic test to identify whether a person has HIV or the Coronavirus.
To accelerate and fully execute the successful production of the multiple monoclonal antibodies, the subject of the Company's intellectual property (specifically the numerous monoclonal antibodies (mAbs) targeting both human and animal viruses), the Company continuously engages with numerous entities to accelerate its progress toward production, testing, and delivery of successful therapeutics. Entities with whom the Company is working include other Biotech Companies having:
Technology and processes for accelerating the production of monoclonal antibodies that target critical virus sites identified by the Company using its A.I. platform. The Company has identified critical conserved target sites on 20 viruses, including human and animal viruses, and is engaging with biotech companies having expertise in accelerating the production of such antibodies.
Related, synergistic or complimentary therapeutics and business structure for the purpose of potential combination with other biotech entities.
Expertise in providing specialized peptides having precise amino acid sequences corresponding to the precise target sites on both the Coronavirus and HIV viruses which are then used in the Company’s Texas lab against which mAbs are being produced. This strategy accelerates the production of the mAbs for further development.
Specialized cell sorting technology that is complementary to the process used in the Company’s lab to accelerate production of mAbs for advancing production.
Expertise in hybridoma production techniques for producing mAbs using hybridoma methodologies complementary to the process used in the Company's lab.
Animal trials centers, both in the U.S. and abroad, for the preparation of animal trials.
Promotional entities with specialized expertise in targeting large funding sources for the purpose of raising the substantial funds needed for the production of the recombinant mAbs necessary for future trials and for conducting animal trials.
As to each of these entities and those with whom the Company currently works on an ongoing basis, the Company has entered into NDAs (Nondisclosure Agreements) necessary to preserve and protect the Company plans and intellectual property being discussed and exchanged between the parties. These contractual restrictions are critical for the Company and its partners. Maintenance of strict confidentiality is essential to preserving intellectual property rights (patent rights) which are now being sought and will be sought in the future. Premature disclosure of information can bar the right to seek patent protection at a later date. The Company is not able to share specific details regarding arrangements regarding these NDAs.
The term of these NDAs is not time limited. The term extends until the later of five (5) years from the Effective Date or "until such time as the proprietary information is publicly known and made generally available". This provision is necessary because under Patent Laws an issued patent may be invalidated where the patent is filed subsequent to public disclosure of the invention claimed. In view of this limitation, the Company makes no public disclosure of information subject to NDAs and inventions covered by them. Additionally, certain technical information shared with companies with whom the Company has entered into an NDA may not be included in a patent application, but rather the subject technical information is maintained as Company confidential ("secret") indefinitely. Also, in these Agreements, the parties generally agree not to reveal the names of the contracting parties for a specified period.
The Company is very confident in its Artificial Intelligence empowered Intellectual Property Portfolio. It has allowed the Company to claim exclusive rights on an international stage covering critical target sites on numerous human and animal viruses. This places the Company on an equal level with the largest biotech companies in that the Company is the first to identify and patent critical sites on many human and animal viruses. This same technology and strategy are being implemented by the Company on new viruses, human or animal. The Company identified the conserved sites on the Monkeypox Virus even before the World Health Organization declared it a global health emergency last week.
The Company believes that its extensive patent portfolio will provide a return on investment through partnering or licensing technology covered by multiple international patents.
Enzolytics Artificial Intelligence Platform
Enzolytics has a wholly owned Artificial Intelligence platform that:
1. Permits early drug discovery and development
2. Builds an Intellectual Property Portfolio
3.
is the SEC looking into criminal fraud at ENZC?
is it true the SEC is investigating enzc for criminal fraud??
ENZC management have a history of lying. The sp reflects just that .035 cents and no news in slight.Their malfeasance has cost longs and is at the point of criminal fraud!
from the pr BUT charles is looking out for enzc investors LOL.How stupid do they think we are?????? they are so insulting .
I. Claiming an Ordinary Theft Loss Deduction
A. General Rule Under Section 165
Deductions for theft losses are governed by section 165(a), which provides that there shall be allowed as a deduction any loss
sustained during the tax year that is not compensated by insurance or otherwise.
Section 165(e) specifies that any loss arising from "theft" shall be treated as sustained during the tax year in which the taxpayer
discovers the loss (that is, a disposition is not required).8 In general, the taxpayer does not have to prove when the loss actually occured.
However when our money was stolen as in this case and we were not fully reimbursed,you can claim it as an ordinary loss after the fund did not totally make you whole.
It may be better to let it go bankrupt ,then it can be used as ordinary loss on a total tax loss after they finalize the fund.
maga sounds like something big pharma would do ,to destroy co.
Enzolytics plans U.S. launch of its nutritional supplement this month
March 10 2022 - 02:18PM LOL enzc has nothing thats why its worh 4 cents
enzc management are scmbags end of story! Who do they think they are and how do they get away with lying to investors ? Does the SEC just let management lie? in the OTC ?where is the financial audit?
Time to look into lawsuit for fraud and malfeasance. Enzc has a reponsibilty to investors who they lied to for last 18 months ,when will it end? byer beware red flags all over the place no financial audit just lies lies and more lies. This is one big pile of shit.
maga continue to paint the picture you are spot on.ENZC are despicable individuals who pretent to help with disease and health But dont have the professionalism to communicate with investors who placed their hard earned money on the company .This is an old game use investor empathy for helping the sick and diseased with a new twist science instead of my snake oil .ENZC suck! They have a lot of nerve treating their investors like shit.
start the lawsuits for fraud and malfeasance !enzc have lied multiple times on record
Start the lawsuits for lying and malfeasance.
lawsuits for fraud coming sooooon!
lawsuits coming soooooon! fraud ,malfeasance,and lying to investors
Lawsuits coming sooooon!!!
How do you know enzc has an NDA they lie all the time.The investors need to look at potential lawsuit as an option .Just need lawyer to start to get misleading statements and other incriminating evidence together.NOW is the time to start as this has no bottom as enzc management obviously dont care about stock price or their investors. Something is not right here!!! Getting out of here with ordinary tax loss because of fraud , theft , or malfeasance is much better economicly,its a full tax deduction .ENZC need to be put on notice asap this has gone too far.
The market just said FU to enzc and all their bullshit and lies.The stock price is all that matters!!!!!!!!!
Well said extreme1 everyone can see they in over their heads.Why dont they see it??
We have 2 types of investors here, peeps who got in early and purchased low ,and others who are underwater and cant sell for a huge loss.The believers have a mind set of I,am still holding a profit and can wait it out,the second group read the selective vaugue wording with no end in sight,now hiding behind? NDA ? .The stock price is what determines our mindset watching it go down everyday for the last 18 months is erroding any believe in the company.ENZC is responsible and have self inflicted daily losses with lies and misleading PRs from Tom and Charles.WHY do they continue to use this type of wording ,promise and not produce , if they are trying to be transperant and honest when it comes off as deceitful to majority of their investors.? What else can you believe ,NO one wants continue to lose money in the OTC in stinky pinky land.The news from the last 48 hrs was not enough to convince the market of anything good ,it dropped anothe 5% it has passed the point patience ,yes bio takes time BUT how the company handles the wait makes a big differnce.ENZC has failed in transperancy, they should sell their patents asap and continue with bio developement.Who knew, when you purchase enzc you are in a 5 year process?
I should have sold on the first YIELD sign.They may be smart but they cant run a company!
spot on 1 oilguy.ENZC has treated its long investors badly .Lying ,misleading ,and lack of communication ,there all unexceptable but ALL of them have happened.Now with a daily decrease on our hard earned money most of us are underwater.When will their shitty attitude toward their investors change .? They have NO idea how to communicate and build a sp that represents their progress ,we have watched and listened to them for over 2 years and they are reponsible for the poor results of the stock price. The only truthful statement I can remember is "dont worry about the daily stock price" the part he didnt say because this is going to take years for you to show any profit. Today sp at 18 month low and ENZC still wont release financial audit they just suck!
ALL speculation NO facts on progress. Just HOPE and big ideas .YOU dont have funding till you have it in the bank !More bullshit from amother stinky pinky..ENZC the OTC market said your stock is worth 5 cents and is going down everyday in case you care.IDIOTS